Showing results (391-400 of 445) with videos related to
Sort By:
Pageof 45
Cancer Chemotherapy and Pharmacology|January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.The Oncologist|February 23, 2013
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerMichael S Lee, Harvey J Mamon, Theodore S Hong, et al.Scientific Reports|February 12, 2020
Double and Triple Ionisation of Isocyanic AcidJ H D Eland, R J Squibb, A J Sterling, et al.Diabetic Medicine : a Journal of the British Diabetic Association|January 30, 2007
Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS studyE S C Korf, E C W van Straaten, F-E de Leeuw, et al.Journal of Neurology|December 25, 2012
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosisH Vrenken, M Jenkinson, M A Horsfield, et al.Lancet (London, England)|October 10, 2009
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialG Comi, V Martinelli, M Rodegher, et al.Neurobiology of Aging|June 27, 2006
Clinical significance of corpus callosum atrophy in a mixed elderly populationC Ryberg, E Rostrup, M B Stegmann, et al.Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.BMC Cancer|July 15, 2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancerJames M Cleary, Harvey J Mamon, Jackie Szymonifka, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialZev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.Pageof 45